FMR LLC & Abigail Johnson Trim Terns Pharma Stake to 4.839%
Ticker: TERN · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1831363
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, ownership-change, amendment, biotech
TL;DR
**FMR LLC and Abigail Johnson slightly cut their Terns Pharma stake to 4.839%.**
AI Summary
FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their holdings in Terns Pharmaceuticals, Inc. (TERNS). As of February 9, 2024, they collectively beneficially own 2,990,402 shares of common stock, representing 4.839% of the company. This is an amendment to a previous filing, indicating a slight decrease in their percentage ownership from a prior filing, which could signal a minor shift in their investment strategy for Terns Pharmaceuticals.
Why It Matters
This filing shows that a significant institutional investor, FMR LLC, and its leader, Abigail P. Johnson, still hold a substantial stake in Terns Pharmaceuticals, but their reduced percentage ownership might suggest a slight decrease in their conviction or a portfolio rebalancing.
Risk Assessment
Risk Level: low — The change in ownership percentage is minor, and FMR LLC remains a significant holder, indicating no immediate major risk to the stock.
Analyst Insight
Investors should note that a major institutional investor has slightly reduced its stake, which could be a minor rebalancing or a subtle signal of changing sentiment. It warrants monitoring future filings for further changes in FMR LLC's position.
Key Numbers
- 2,990,402 — Shares Beneficially Owned (Represents the total common stock shares FMR LLC and Abigail P. Johnson collectively own in Terns Pharmaceuticals.)
- 4.839% — Percent of Class (Indicates the proportion of Terns Pharmaceuticals' common stock owned by FMR LLC and Abigail P. Johnson, showing their significant, though slightly reduced, stake.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, principal owner of FMR LLC
- Terns Pharmaceuticals, Inc. (company) — subject company, issuer of common stock
- 2,990,402 (dollar_amount) — total shares beneficially owned by FMR LLC and Abigail P. Johnson
- 4.839% (dollar_amount) — percentage of class beneficially owned
Forward-Looking Statements
- FMR LLC will maintain a significant, but potentially slightly reduced, stake in Terns Pharmaceuticals over the next year. (FMR LLC) — medium confidence, target: 2025-02-09
FAQ
Who are the primary reporting persons in this SC 13G/A filing for Terns Pharmaceuticals, Inc.?
The primary reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing for both entities.
What is the total number of shares of Terns Pharmaceuticals, Inc. common stock beneficially owned by FMR LLC and Abigail P. Johnson?
FMR LLC and Abigail P. Johnson each beneficially own 2,990,402 shares of Terns Pharmaceuticals, Inc. common stock, as reported in Item 7 and Item 9 for both reporting persons.
What percentage of Terns Pharmaceuticals, Inc.'s common stock do FMR LLC and Abigail P. Johnson collectively own?
FMR LLC and Abigail P. Johnson each own 4.839% of the class of Terns Pharmaceuticals, Inc. common stock, as indicated in Item 11 for both reporting persons.
What is the CUSIP number for Terns Pharmaceuticals Inc. common stock mentioned in the filing?
The CUSIP number for Terns Pharmaceuticals Inc. common stock is #880881107, as stated at the beginning of the Schedule 13G Amendment No.3 section and in Item 2(e).
Under which rule is this Schedule 13G/A filed?
This Schedule 13G/A is filed pursuant to Rule 13d-1(b), as indicated by the 'x' in the appropriate box at the beginning of the filing and in Item 3.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on February 9, 2024 by Abigail P. Johnson regarding Terns Pharmaceuticals, Inc. (TERN).